Form D · Pharmaceuticals
STEMLINE THERAPEUTICS INC
New York, NY · CIK 0001264587
Offering snapshot reported Jan 17, 2012 · SEC filing
- Reported sold
- $740K Indefinite offering
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 2, 2012 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 17, 2012 | Initial | $740,000 | No comparison | 16 | SEC filing |
| Apr 27, 2010 | Initial | $600,000 | No comparison | 20 | SEC filing |
| Mar 29, 2010 | Initial | $1,250,000 | No comparison | 5 | SEC filing |
| Oct 23, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0 (estimated)
- Finders' fees
- $0 (estimated)
- Form D file number
- 021-172007
Source: Form D, filed Jan 17, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ronald Bentsur | Director |
| Ivan Bergstein | Director, Executive |
| Ivan Bergstein, M.D. | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1675 York Avenue, Suite 34 L
New York, NY, 10128
New York, NY, 10128